Back to search
FDAFDA · Food and drugs·Recall number D-0275-2024

Budesonide Extended-Release Tablets 9mg, 30-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054 USA, NDC 0591-2510-30

Published February 7, 2024 · Recall initiated: January 8, 2024

Summary

FDA records drug Class II recall D-0275-2024, published February 7, 2024 and initiated January 8, 2024. Recalling firm: Teva Pharmaceuticals USA, Inc; Status: Ongoing; Reported quantity: 10,672 30-count bottles; Lot: Lot # 100047273; Exp. 07/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email if BUDESONIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
BUDESONIDE
Manufacturer
Teva Pharmaceuticals USA, Inc
Distributor
Nationwide
UPC
0305912510303
Lot
Lot # 100047273; Exp. 07/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Budesonide Extended-Release Tablets 9mg, 30-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054 USA, NDC 0591-2510-30 recalled?

Yes. FDA published recall D-0275-2024 on February 7, 2024. Reported hazard: Failed Dissolution Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: BUDESONIDE. UPC: 0305912510303.